Clinical Trials Directory

Trials / Completed

CompletedNCT02107599

The Feasibility of Florbetapir Quantitation in Europe

A Study to Evaluate the Improvement in Reader Accuracy When Using a Read Method That Incorporates Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Visual Interpretation of Amyvid Brain Scans

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
96 (actual)
Sponsor
Avid Radiopharmaceuticals · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.

Conditions

Interventions

TypeNameDescription
DRUGFlorbetapir (18F)No Florbetapir (18F) will be administered in this study.

Timeline

Start date
2014-03-01
Primary completion
2014-05-01
Completion
2014-05-01
First posted
2014-04-08
Last updated
2015-07-09
Results posted
2015-07-09

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02107599. Inclusion in this directory is not an endorsement.

The Feasibility of Florbetapir Quantitation in Europe (NCT02107599) · Clinical Trials Directory